Verastem, Inc. (VSTM) Stock Price & Analysis
Verastem, Inc. (VSTM) rose 4.09% to USD 3.82 as of June 10, 2026 at 03:07 UTC, according to Nexqual real-time market data.
VSTM last closed at USD 3.67; the session ranged USD 3.55–3.86 on volume of 3,039,045 shares. Market capitalization is $335.68M, with a 52-week range of USD 3.55–11.25 (NCM). Source: Nexqual, June 10, 2026 at 03:07 UTC.
Key Statistics (as of June 10, 2026 at 03:07 UTC)
| Price | USD 3.82 |
|---|---|
| Change | ▲ 4.09% (up) |
| Previous Close | USD 3.67 |
| Open | USD 3.75 |
| Day Range | USD 3.55 – 3.86 |
| 52-Week Range | USD 3.55 – 11.25 |
| Volume | 3,039,045 shares |
| Market Cap | $335.68M |
| Exchange | NCM |
Technical Analysis (VSTM)
Nexqual's technical model rates VSTM "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:07 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 32.89 (neutral) |
| vs SMA50 | Below (USD 5.1) |
| MACD | -0.41 (negative) |
Analyst Ratings (VSTM)
Wall Street analysts rate VSTM "Strong Buy" based on 8 analysts, with a mean price target of USD 16 (range USD 14–18), per Nexqual as of June 10, 2026 at 03:07 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 16 |
| High Target | USD 18 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (VSTM)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.45 |
| Revenue Estimate | $23.24M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.43 vs est -0.47 ▲ beat |
| 2025-12-31 | USD -0.46 vs est -0.5 ▲ beat |
| 2025-09-30 | USD -0.54 vs est -0.61 ▲ beat |
| 2025-06-30 | USD -0.63 vs est -0.75 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financials & Fundamentals (VSTM)
| Total Revenue | $49.59M |
|---|---|
| Gross Margin | +85.13% |
| Operating Margin | -240.46% |
| Profit Margin | +0.00% |
| ROE | -786.15% |
| Debt / Equity | 104.52 |
| Current Ratio | 3.04 |
| Total Cash | $181.68M |
| Total Debt | $85.47M |
| Free Cash Flow | $-92.68M |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financial Health Score (VSTM)
Nexqual rates Verastem, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:07 UTC.
| Growth | Strong — Revenue +209% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $182M cash vs $85M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$93M, burning cash |
| Efficiency | Critical — ROE -786%, ROA -59.4% |
Ownership (VSTM)
| Insider Ownership | +0.95% |
|---|---|
| Institutional Ownership | +93.57% |
| Shares Outstanding | 87.87M |
| Float | 70.40M |
| Short % of Float | +24.29% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Leadership (VSTM)
Verastem, Inc. is led by Daniel W. Paterson (age 64), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:07 UTC.
| President, CEO & Director | Daniel W. Paterson (age 64) |
|---|---|
| Chief Financial Officer | Daniel Calkins (age 37) |
| President of Development & Director | Michael Glen Kauffman (age 62) |
| Executive Vice President of Portfolio Strategy & Operations | Lori Horvat |
| Chief Scientific Officer | Jonathan Pachter (age 67) |
Major Backers & Investors (VSTM)
Notable institutional backers of Verastem, Inc. include RTW Investments LP, Deep Track Capital, Lp, Armistice Capital, LLC, according to Nexqual as of June 10, 2026 at 03:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 7.48% |
| Deep Track Capital, Lp | 6.53% |
| Armistice Capital, LLC | 5.23% |
| Nantahala Capital Management, LLC | 4.08% |
| Stonepine Capital Management, LLC | 3.76% |
| Foresite Capital Management VI LLC | 3.58% |
| Millennium Management | 2.74% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.16% |
| Vanguard Group | 7.77% |
| State Street | 6.62% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
From Verastem, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
- Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
- It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans.
- In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc. | USD 8.69 | ▼ 4.3% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| TLPH | Talphera, Inc. | USD 0.82 | ▲ 4.56% |
| RIGL | Rigel Pharmaceuticals, Inc. | USD 30.72 | ▲ 2.64% |
| VTGN | VistaGen Therapeutics, Inc. | USD 0.54 | ▼ 0.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:07 UTC. This page is informational and not investment advice.